Literature DB >> 17725178

Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation.

R M Menon1, M H Adams, M A González, D S Tolbert, J H Leu, E A Cefali.   

Abstract

OBJECTIVE: To characterize plasma and urine pharmacokinetics of niacin and its metabolites after oral administration of 2,000 mg of extended-release (ER) niacin in healthy male volunteers.
METHODS: Niacin ER was administered to 12 healthy male subjects following a low-fat snack. Plasma was collected for 12 h post dose and was analyzed for niacin, nicotinuric acid (NUA), nicotinamide (NAM) and nicotinamide-N-oxide (NNO). Urine was collected for 96 h post dose and analyzed for niacin and its metabolites, NUA, NAM, NNO, N-methylnicotinamide (MNA) and N-methyl-2-pyridone-5-carboxamide (2PY).
RESULTS: Mean niacin Cmax and AUC(0-t) values were 9.3 microg/ml and 26.2 microg x h/ml and were the highest of all analytes measured. Peak niacin and NUA levels occurred at 4.6 h (median) while tmax for NAM and NNO were 8.6 and 11.1 h, respectively. The mean plasma terminal half-life for niacin (0.9 h) and NUA (1.3 h) was shorter as compared to NAM (4.3 h). Urine recovery of niacin and metabolites accounted for 69.5% of the administered dose; only 3.2% was excreted as niacin. The highest recovery was for 2PY (37.9%), followed by MNA (16.0%) and NUA (11.6%). Mean half-lives for 2PY and MNA calculated in urine were 12.6 and 12.8 h, respectively.
CONCLUSIONS: Niacin was extensively metabolized following oral administration, and about 70% of the administered dose is recovered in urine in 96 h as niacin, NUA, MNA, NNO, NAM and 2PY. The plasma levels of the parent niacin were higher than its metabolites though only about 3% of the unchanged drug is recovered in urine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725178     DOI: 10.5414/cpp45448

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  13 in total

1.  Gender differences in pharmacokinetics of a combination tablet of niacin extended-release/simvastatin in healthy Chinese volunteers.

Authors:  Xiao-lin Wang; Man Liu; Man Yang; Ya-nan Zhang; Dan Zhang; Li-na Zhang; Jing Han; Hui-chen Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-18       Impact factor: 2.441

2.  Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Authors:  Thomas O'Brien; Jason Oeh; Yang Xiao; Xiaorong Liang; Alexander Vanderbilt; Ann Qin; Lulu Yang; Leslie B Lee; Justin Ly; Ely Cosino; Jennifer A LaCap; Annie Ogasawara; Simon Williams; Michelle Nannini; Bianca M Liederer; Peter Jackson; Peter S Dragovich; Deepak Sampath
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.

Authors:  Alexander Michael Real; Shangyu Hong; Pavlos Pissios
Journal:  Drug Metab Dispos       Date:  2012-12-21       Impact factor: 3.922

4.  Nicotinic acid activates the capsaicin receptor TRPV1: Potential mechanism for cutaneous flushing.

Authors:  Linlin Ma; Bo Hyun Lee; Rongrong Mao; Anping Cai; Yunfang Jia; Heather Clifton; Saul Schaefer; Lin Xu; Jie Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03-27       Impact factor: 8.311

5.  Antiatherosclerotic Effects of 1-Methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient Mice: A Comparison with Nicotinic Acid.

Authors:  Lukasz Mateuszuk; Agnieszka Jasztal; Edyta Maslak; Marlena Gasior-Glogowska; Malgorzata Baranska; Barbara Sitek; Renata Kostogrys; Agnieszka Zakrzewska; Agnieszka Kij; Maria Walczak; Stefan Chlopicki
Journal:  J Pharmacol Exp Ther       Date:  2015-12-02       Impact factor: 4.030

Review 6.  Niacin extended-release/simvastatin.

Authors:  Mark Sanford; Monique P Curran
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes.

Authors:  Nady Braidy; Jade Berg; James Clement; Fatemeh Khorshidi; Anne Poljak; Tharusha Jayasena; Ross Grant; Perminder Sachdev
Journal:  Antioxid Redox Signal       Date:  2018-05-11       Impact factor: 8.401

8.  Niacin promotes revascularization and recovery of limb function in diet-induced obese mice with peripheral ischemia.

Authors:  Dominic K T Pang; Zengxuan Nong; Brian G Sutherland; Cynthia G Sawyez; Debra L Robson; Jelena Toma; J Geoffrey Pickering; Nica M Borradaile
Journal:  Pharmacol Res Perspect       Date:  2016-04-14

Review 9.  Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics.

Authors:  Harsh Goel; Richard L Dunbar
Journal:  Curr Atheroscler Rep       Date:  2016-04       Impact factor: 5.113

Review 10.  N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin.

Authors:  Aurélie Lenglet; Sophie Liabeuf; Sandra Bodeau; Loïc Louvet; Aurélien Mary; Agnès Boullier; Anne Sophie Lemaire-Hurtel; Alexia Jonet; Pascal Sonnet; Said Kamel; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2016-11-15       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.